Tıp Fakültesi / Faculty of Medicinehttp://hdl.handle.net/11727/14032024-03-29T07:44:06Z2024-03-29T07:44:06ZLong Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMTGarderet, LaurentLuuk, Gras, Sr.Koster, LindaRovira, MontserratVincent, LaureKobbe, GuidoPillai, SrinivasDeeren, DriesKaufmann, MartinKuball, JurgenOzdogu, HakanPascual, Maria JesusPassweg, Jakob R.Rye, AdamSalmenniemi, UrpuSnowden, JohnLarsen, Thomas StaufferLeleu, XavierGastaud, LaurisDrozd-Sokolowska, JoannaRaj, KavitaBeksac, MeralSchonland, StefanHayden, Patrick JohnMcLornan, Donal P.http://hdl.handle.net/11727/119592024-03-29T07:36:37Z2023-01-01T00:00:00ZLong Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT
Garderet, Laurent; Luuk, Gras, Sr.; Koster, Linda; Rovira, Montserrat; Vincent, Laure; Kobbe, Guido; Pillai, Srinivas; Deeren, Dries; Kaufmann, Martin; Kuball, Jurgen; Ozdogu, Hakan; Pascual, Maria Jesus; Passweg, Jakob R.; Rye, Adam; Salmenniemi, Urpu; Snowden, John; Larsen, Thomas Stauffer; Leleu, Xavier; Gastaud, Lauris; Drozd-Sokolowska, Joanna; Raj, Kavita; Beksac, Meral; Schonland, Stefan; Hayden, Patrick John; McLornan, Donal P.
2023-01-01T00:00:00ZClinical Features, Etiological Reasons, and Treatment Results in Patients Who Developed Acute Acquired Nonaccomodative Esotropia (August, 10.1007/S10792-022-02458-4, 2022)Sefi-Yurdakul, Nazifehttp://hdl.handle.net/11727/119582024-03-27T13:31:23Z2023-01-01T00:00:00ZClinical Features, Etiological Reasons, and Treatment Results in Patients Who Developed Acute Acquired Nonaccomodative Esotropia (August, 10.1007/S10792-022-02458-4, 2022)
Sefi-Yurdakul, Nazife
2023-01-01T00:00:00ZGraft-Versus-Host Disease and Relapse/Rejection-Free Survival After Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: A Comprehensive Analysis from the SAAWP of the EBMTDevillier, RaynierEikema, Dirk-JanDufour, CarloAljurf, MahmoudWu, DepeiMaschan, AlexeiKulagin, AlexanderHalkes, Constantijn J. M.Collin, MatthewSnowden, JohnRenard, CecileGanser, ArnoldSykora, Karl-WalterGibson, Brenda E.Maertens, JohanItala-Remes, MaijaCorti, PaolaCornelissen, JanBornhaeuser, MartinColorado Araujo, MercedesOzdogu, HakanRisitano, AntonioSocie, Gerardde latour, Regis Peffaulthttp://hdl.handle.net/11727/119562024-03-27T08:12:27Z2023-01-01T00:00:00ZGraft-Versus-Host Disease and Relapse/Rejection-Free Survival After Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: A Comprehensive Analysis from the SAAWP of the EBMT
Devillier, Raynier; Eikema, Dirk-Jan; Dufour, Carlo; Aljurf, Mahmoud; Wu, Depei; Maschan, Alexei; Kulagin, Alexander; Halkes, Constantijn J. M.; Collin, Matthew; Snowden, John; Renard, Cecile; Ganser, Arnold; Sykora, Karl-Walter; Gibson, Brenda E.; Maertens, Johan; Itala-Remes, Maija; Corti, Paola; Cornelissen, Jan; Bornhaeuser, Martin; Colorado Araujo, Mercedes; Ozdogu, Hakan; Risitano, Antonio; Socie, Gerard; de latour, Regis Peffault
Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe idiopathic aplastic anemia (SAA) has improved in recent years, approaching 75% at 5 years. However, an SAA-adapted composite endpoint, graft-versus-host disease (GvHD) and relapse/rejection-free survival (GRFS), may more accurately assess patient outcomes beyond survival. We analyzed GRFS to identify risk factors and specific causes of GRFS failure. Our retrospective analysis from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation included 479 patients with idiopathic SAA who underwent allo-HSCT in two conventional situations: i) upfront allo-HSCT from a matched related donor (MRD) (upfront cohort), and ii) allo-HSCT for relapsed or refractory SAA (rel/ref cohort). Relevant events for GRFS calculation included graft failure, grade 3-4 acute GvHD, extensive chronic GvHD, and death. In the upfront cohort (n=209), 5-year GRFS was 77%. Late allo-HSCT (i.e., >6 months after SAA diagnosis) was the main poor prognostic factor, specifically increasing the risk of death as the cause of GRFS failure (hazard ratio [HR]=4.08; 95% confidence interval [CI]: 1.41-11.83; P=0.010). In the rel/ref cohort (n=270), 5-year GRFS was 61%. Age was the main factor significantly increasing the risk of death (HR=1.04; 95% CI: 1.02-1.06; P<0.001), acute GvHD (HR=1.03; 95% CI: 1.00-1.07; P=0.041), and chronic GvHD (HR=1.04; 95% CI: 1.01-1.08; P=0.032) as the cause of GRFS failure. GRFS after upfront MRD allo-HSCT was very good, notably with early allo-HSCT, confirming that younger patients with an MRD should be transplanted immediately. GRFS was worse in cases of salvage allo-HSCT, most notably in older patients, questioning the utility of allo-HSCT earlier in the disease course.
2023-01-01T00:00:00ZLong-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective StudySavas, Emine MerveYilmaz, SedaDikyar, Ayse Asena BaserOzkurt, Zubeyde NurOcal, RamazanCan, FerdaPepeler, SezginKaynar, Lale AydinGokcen, SanemYildiz, AbdulkerimAlbayrak, MuratKarakus, SemaCeneli, OzcanYagci, Muncihttp://hdl.handle.net/11727/119552024-03-27T08:03:02Z2023-01-01T00:00:00ZLong-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
Savas, Emine Merve; Yilmaz, Seda; Dikyar, Ayse Asena Baser; Ozkurt, Zubeyde Nur; Ocal, Ramazan; Can, Ferda; Pepeler, Sezgin; Kaynar, Lale Aydin; Gokcen, Sanem; Yildiz, Abdulkerim; Albayrak, Murat; Karakus, Sema; Ceneli, Ozcan; Yagci, Munci
Objective: The discovery of imatinib was a milestone for chronic myeloid leukemia (CML). As the life expectancy of CML patients has approached that of the general population, research has shifted towards improving quality of life and economic considerations. After 2010, it was shown that some patients could maintain molecular response even after discontinuing imatinib. This national multicenter prospective cohort study aimed to observe the long-term consequences of discontinuing imatinib therapy in adult chronic-phase CML patients.
Materials and Methods: We enrolled 41 CML patients from 4 different centers in this non-randomized single-arm trial. Molecular responses of all patients were re-evaluated using real-time polymerase chain reaction at a single center. The median follow-up time after imatinib discontinuation was 48 months (minimum-maximum: 6-81 months).
Results: The rate of molecular relapse-free survival at 48 months was 33.2% (confidence interval: 48.2-18.2). Twenty-seven of 41 patients lost their major molecular response, treatment was started again, and deep molecular response was re-achieved with imatinib in all cases. There was no significant relationship between molecular relapse and clinical factors such as duration of treatment or molecular response status. Discontinuing imatinib resulted in savings of approximately 4,392,000 Turkish lira or 245,150 US dollars.
Conclusion: Tyrosine kinase inhibitor discontinuation with close molecular monitoring is a safe option and provides important national economic benefits for chronic phase CML patients. This approach should be considered for all eligible patients. This is the first tyrosine kinase inhibitor discontinuation study from Turkiye.
2023-01-01T00:00:00Z